Stereotaxis
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 26.6m | 35.0m | 28.1m | 26.8m | 26.6m | 41.3m | 67.1m |
% growth | (8 %) | 32 % | (20 %) | (5 %) | (1 %) | 56 % | 62 % |
EBITDA | (6.7m) | (15.1m) | (18.8m) | (21.2m) | (10.4m) | (7.1m) | 2.8m |
% EBITDA margin | (25 %) | (43 %) | (67 %) | (79 %) | (39 %) | (17 %) | 4 % |
Profit | (6.6m) | (10.7m) | (18.3m) | (20.7m) | (20.3m) | (16.0m) | (9.4m) |
% profit margin | (25 %) | (31 %) | (65 %) | (77 %) | (77 %) | (39 %) | (14 %) |
EV / revenue | 13.2x | 13.1x | 5.5x | 4.9x | 7.3x | 4.7x | 2.9x |
EV / EBITDA | -52.3x | -30.5x | -8.3x | -6.2x | -18.6x | -27.3x | 69.3x |
R&D budget | 8.1m | 10.2m | 10.6m | 10.3m | - | - | - |
R&D % of revenue | 31 % | 29 % | 38 % | 38 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Debt | ||
$20.0m | Early VC | ||
N/A | $16.0m | Early VC | |
N/A | N/A | IPO | |
N/A | $10.0m | Post IPO Equity | |
N/A | $24.0m | Post IPO Equity | |
N/A | $10.0m | Post IPO Equity | |
* | $25.0m | Post IPO Equity | |
Total Funding | €32.7m |
Recent News about Stereotaxis
EditStereotaxis is a leading MedTech company specializing in innovative robotic technologies for the treatment of arrhythmias. The company operates in the healthcare sector, providing advanced robotic catheter ablation systems that enable precise and safe treatment of heart rhythm disorders. Stereotaxis primarily serves healthcare professionals, including physicians and hospitals, who are involved in the treatment of arrhythmias. The company’s business model revolves around the development, manufacturing, and sale of its robotic systems, as well as providing ongoing support and maintenance services. Revenue is generated through the sale of these systems and associated services. Stereotaxis is recognized for its Robotic Magnetic Navigation (RMN) System, which has been successfully implemented in various healthcare facilities, enhancing the precision and safety of arrhythmia treatments. The company continues to innovate and expand its market presence, aiming to improve patient outcomes and advance the field of endovascular treatment.
Keywords: Robotic Catheter Ablation, Arrhythmia Treatment, MedTech, Healthcare, Precision, Safety, Physicians, Hospitals, RMN System, Endovascular Treatment.